Network meta-analysis of first-line treatments for metastatic urothelial carcinoma
- VernacularTitle:转移性尿路上皮癌一线治疗方案的网状Meta分析
- Author:
Xuejia QIU
1
;
Bingnan REN
1
;
Lingzhi FANG
1
;
Yufei LIAN
1
;
Yupei WU
1
;
Zhanjun DONG
1
Author Information
1. Department of Pharmacy，Hebei General Hospital/Hebei Key Laboratory of Clinical Pharmacy，Shijiazhuang 050051，China
- Publication Type:Journal Article
- Keywords:
metastatic urothelial carcinoma;
network meta-analysis;
pembrolizumab;
enfortumab vedotin;
gemcitabine
- From:
China Pharmacy
2024;35(22):2815-2821
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To systematically evaluate the effectiveness of different treatment regimens as first-line treatment for metastatic urothelial carcinoma （UC） using a network meta-analysis （NMA） approach. METHODS Electronic databases including PubMed， the Cochrane Library， Embase， Wanfang Data， CNKI， and VIP were searched for randomized controlled clinical trials （RCTs） on first-line treatment for metastatic UC from January 1， 2010 to January 31， 2024. After literature screening and data extraction， a risk of bias assessment of included studies was conducted. R software （version 4.3.2） was used to perform the NMA. RESULTS A total of 11 RCTs involving 14 treatment interventions were included. No significant differences were noted in objective response rate among groups， with the combination of pembrolizumab， gemcitabine and cisplatin having the highest probability of ranking first. Regarding progression-free survival （PFS） and overall survival （OS）， no significant differences were observed among groups， while enfortumab vedotin combined with pembrolizumab showed a trend towards better PFS extension compared to gemcitabine combined with cisplatin [HR＝0.45， 95%CI（0.20，1.06）， P＝0.049]， and it had the highest probability of ranking first in both PFS and OS. CONCLUSIONS The combination of enfortumab vedotin and pembrolizumab may have an advantage in prolonging survival in the first-line treatments for metastatic UC.
